Shots:
- Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical for the exclusive development & commercialization of KG006 in Japan
- As per the deal, Taisho will acquire exclusive rights to develop & commercialise KG006 in Japan, with Kaigene receiving $5M upfront, up to $22M & ¥57.5B (~$351M) in development, regulatory & sales milestones, plus tiered royalties on Japan sales. Kaigene retains global rights outside Greater China & Japan through its Celltrion alliance
- KG006 (CT-P77) is a next-gen FcRn inhibitor with a novel antibody structure, offering deep antibody degradation, durability & convenient SC dosing
Ref: PRNewsWire | Image: Kaigene & Taisho Pharmaceutical | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
